ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0823

Pulmonary Manifestations in VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome: A Systematic Literature Review

Koushan Kouranloo1, Athea Ashley2, Sizheng Zhao3 and Mrinalini Dey4, 1Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom, 2School of Medicine, University of Liverpool, Liverpool, United Kingdom, 3University of Manchester, Liverpool, United Kingdom, 4Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, United Kingdom

Meeting: ACR Convergence 2022

Keywords: Autoinflammatory diseases, pulmonary

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster II

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: VEXAS (vacuoles, E1 enzyme, X-linked, auto-inflammatory, somatic) syndrome is a newly described auto-inflammatory disease, characterised by somatic mutation of UBA1 [1]. A consistent feature of many cases is pulmonary infiltrates, or respiratory failure.

This systematic review aimed to summarise the respiratory manifestations in VEXAS syndrome, described in the literature to date.

Methods: All published articles discussing VEXAS syndrome were included, until May 2022. Initial scoping reviews were performed to optimize the search strategy. Given the relative recency of VEXAS in the literature, the final search was kept deliberately broad to ensure all relevant papers were captured. Medline, Embase, International Network of Agencies for Health Technology Assessment, PsychInfo and Cochrane Databases were searched.

The research question was: What are the pulmonary manifestations in patients with VEXAS syndrome? The search was restricted to English-language articles and those discussing clinical presentation of disease. All article types were deemed eligible except opinion articles and reviews.

Titles and abstracts were screened. Articles meeting inclusion criteria were examined by one author, with 20% validity screening. In addition to basic demographics, information was extracted on type and prevalence of pulmonary manifestations, disease associations at first presentation of VEXAS, and, if mentioned, author conclusions on pulmonary involvement.

Results: Initially, 219 articles were retrieved with 36 ultimately included (18 case reports, 18 case series; Figure 1). A pooled total of 269 patients with VEXAS were included, 98.6% male, mean age 66.8 years (SD 7.3) at disease onset. Patients were from: Europe (n=181); North America (62); South America (n=1); Asia (n=21); Australasia (n=4).

56.1% had pulmonary involvement at presentation. The most frequently described pulmonary manifestation was infiltrates (43.1%; n=116), followed by pleural effusion (7.4%; n=20) and idiopathic interstitial pneumonia (3.3%; n=9). Other pulmonary manifestations were: nonspecific interstitial pneumonia (n=1), bronchiolitis obliterans (n=3), pulmonary vasculitis (n=6), bronchiectasis (n=1), alveolar haemorrhage (n=1), pulmonary embolism (n=4), bronchial stenosis (n=1), and alveolitis (n=1). With regards co-existing autoimmune diseases, pulmonary involvement was described in patients previously diagnosed with or meeting diagnostic criteria for: relapsing polychondritis, certain vasculitides, systemic lupus erythematosus, Sweet’s syndrome, Behcet’s disease. However, it was not reported which of these patients had particular pulmonary manifestations.

Conclusion: Pulmonary disease is common in patients with VEXAS, frequently described as pulmonary infiltrates. It is unclear if respiratory manifestations are part of the primary disease or a co-existing condition. Epidemiological and larger cohort analyses in VEXAS patients will aid further characterisation of pulmonary involvement and disease management.

References
1. Beck DB et al. Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease. N Engl J Med. 2020 Dec 31.

Supporting image 1

Flow diagram of stages of systematic literature review.
INAHTA= International Network of Agencies for Health Technology Assessment. Cochrane Library encompasses library of: systematic reviews; systematic review protocols; controlled clinical trials.


Disclosures: K. Kouranloo, None; A. Ashley, None; S. Zhao, UCB; M. Dey, None.

To cite this abstract in AMA style:

Kouranloo K, Ashley A, Zhao S, Dey M. Pulmonary Manifestations in VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome: A Systematic Literature Review [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/pulmonary-manifestations-in-vexas-vacuoles-e1-enzyme-x-linked-autoinflammatory-somatic-syndrome-a-systematic-literature-review/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pulmonary-manifestations-in-vexas-vacuoles-e1-enzyme-x-linked-autoinflammatory-somatic-syndrome-a-systematic-literature-review/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology